# BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Source: https://onco.cc/trials/nct07226856/  
OnCo record `nct07226856` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine, nab-paclitaxel and nivolumab in pancreatic cancer, run by Mayo Clinic, now recruiting.

## Summary

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma is a phase 2, interventional study registered as NCT07226856 by Mayo Clinic, with a registry enrolment figure of 43 participants, started 2025-12-12 and due to reach its primary completion in 2028-12-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Gemcitabine; Imzokitug; Magnetic Resonance Imaging; Nab-paclitaxel; Nivolumab. Conditions listed: Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8. Primary outcome: Incidence of significant adverse events (AEs) (Safety Run-in); Objective response rate (Phase II). Pancreatic eligibility wording from the registry: "* Histological confirmation of pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07226856
- Phase: 2
- Setting: Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma
- Sponsor: Mayo Clinic
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT07226856: https://clinicaltrials.gov/study/NCT07226856

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07226856.json